Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for ...

Eli Lilly and Company: Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years 75% of patients achieved a high ...
Pittsburgh QuarterlyOpinion

50 Leaders Give Their Rx for Pittsburgh Mayor Corey O’Connor, Pt. III

We asked Pittsburgh leaders to give their prescriptions for Mayor Corey O’Connor on how to build a bright future for ...

8th Pay Commission latest update: Finance Ministry reveals status of proposed changes, salaries, pensions and fiscal impact

The 8th Pay Commission is now functioning in New Delhi. It will submit recommendations on pay, allowances, and pensions ...

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care ...
Duluth News Tribune

Mandy Pearson leaving UMD women's basketball for St. Thomas

In 11 seasons with the Bulldogs as head coach, UMD won nearly two-thirds of its games, went to the NCAA tournament six times ...